Brought to you by 
Novartis buys Pfizer's Enablex for CHF310.5mm
Mar 2003
Executive Summary
Novartis AG is adding to its primary care portfolio by acquiring Pfizer's drug Enablex (darifenacin), a treatment for overactive bladder, for CHF310.5mm ($225mm).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com